EUVIMEDEUVIMED entdecken
Crossref

Monocytic resilience during chemoradiotherapy is independently associated with survival in IDH-Wildtype glioblastoma

Flavio Donnini, Pierpaolo Pastina, Giuseppe Battaglia, Salvatore Chibbaro, Alfonso Cerase, Valerio Nardone, Isacco Desideri, Francesco Pasqualetti, Alessandra Pascucci, Vincenzo D'Alonzo, Maria Antonietta Mazzei, Giuseppe Minniti und 2 weitere

Journal of Neuro-Oncology · 2026-10 · 180 (1)

DOI: 10.1007/s11060-026-05830-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 13.10.2026. Verfasst von Flavio Donnini und 13 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. Hauptthemen laut MEDLINE: Glioblastoma, Monocytes, Brain Neoplasms, Chemoradiotherapy. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Routine blood counts may capture treatment-related host immune perturbation in glioblastoma, but most studies rely on static pretreatment values. We investigated whether the intra-individual preservation of circulating monocytes during chemoradiotherapy provides prognostic information beyond established clinical factors and other hematologic trajectories.

Methods

We retrospectively analyzed adults with histologically confirmed IDH-wildtype glioblastoma treated with radiotherapy and concurrent temozolomide. Absolute monocyte counts obtained before and at the end of chemoradiotherapy were used to define monocytic resilience as log2(post-treatment/pre-treatment monocyte ratio). Overall survival (OS) was the primary endpoint. Cox models adjusted for MGMT promoter methylation, gross total resection, Karnofsky Performance Status, and age. The ratio was analyzed continuously for primary inference. A post/pre ratio of 0.75 was additionally evaluated as an exploratory, clinically interpretable threshold for two-group Kaplan-Meier visualization and sensitivity analysis.

Results

Among 127 patients, 115 had complete monocyte trajectories and OS data. The primary adjusted model included 102 patients and 86 deaths. The continuous monocyte post/pre ratio was independently associated with OS (HR 0.53 per doubling, 95% CI 0.37–0.76; p = 0.00051). Using the exploratory 0.75 threshold, 52 patients had low resilience (< 0.75) and 63 had preserved resilience (≥ 0.75), with median OS of 10.2 and 17.3 months, respectively (log-rank p = 0.00064). Preserved resilience was associated with lower mortality in univariable Cox analysis (HR 0.50, 95% CI 0.34–0.75; p = 0.00080). Bootstrap resampling showed that outcome-optimized cut-points clustered around this region (median 0.74; IQR 0.70–0.81), although the threshold remains exploratory and requires external validation.

Conclusions

Preservation or recovery of circulating monocytes during chemoradiotherapy was associated with a favorable host-response phenotype in IDH-wildtype glioblastoma. This dynamic signal remained associated with survival after adjustment for established clinical factors, baseline monocyte burden, lymphocyte change, systemic inflammatory imbalance, and measured corticosteroid exposure. External prospective validation, medication-level confounder assessment, and immune phenotyping are required before clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaMonocytesBrain NeoplasmsChemoradiotherapyHumansFemaleRetrospective StudiesMaleMiddle AgedPrognosisIsocitrate DehydrogenaseTemozolomideAdultAgedAntineoplastic Agents, AlkylatingFollow-Up StudiesSurvival Rate

Stichwörter der Autor:innen

BiomarkersChemoradiotherapyCorticosteroidsGlioblastomaImmune resilienceMonocytesSurvival

Substanzen

Isocitrate DehydrogenaseTemozolomideAntineoplastic Agents, AlkylatingIDH1 protein, human

Autor:innen und Institutionen

  • Unit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
  • Unit of Neurosurgery, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy.
  • Unit of Diagnostic Neuroradiology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy.
  • Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, 50134, Florence, Italy.
  • Department of Surgery, Oncology and Gastroenterology, University of Padova, 35122, Padova, Italy.

Zitieren

APA

Donnini, F., Pastina, P., Battaglia, G., Chibbaro, S., Cerase, A., Nardone, V., Desideri, I., Pasqualetti, F., Pascucci, A., D'Alonzo, V., Mazzei, M. A., Minniti, G., Di Giacomo, A. M., & Tini, P. (2026). Monocytic resilience during chemoradiotherapy is independently associated with survival in IDH-Wildtype glioblastoma. Journal of Neuro-Oncology, 180(1). https://doi.org/10.1007/s11060-026-05830-x

Vancouver

Donnini F, Pastina P, Battaglia G, Chibbaro S, Cerase A, Nardone V, et al. Monocytic resilience during chemoradiotherapy is independently associated with survival in IDH-Wildtype glioblastoma. Journal of Neuro-Oncology. 2026;180(1). doi:10.1007/s11060-026-05830-x

BibTeX
@article{Donnini2026,
  author = {Donnini, Flavio and Pastina, Pierpaolo and Battaglia, Giuseppe and Chibbaro, Salvatore and Cerase, Alfonso and Nardone, Valerio and Desideri, Isacco and Pasqualetti, Francesco and Pascucci, Alessandra and D'Alonzo, Vincenzo and Mazzei, Maria Antonietta and Minniti, Giuseppe and Di Giacomo, Anna Maria and Tini, Paolo},
  title = {Monocytic resilience during chemoradiotherapy is independently associated with survival in IDH-Wildtype glioblastoma},
  journal = {Journal of Neuro-Oncology},
  year = {2026},
  volume = {180},
  number = {1},
  doi = {10.1007/s11060-026-05830-x}
}
Kostenlos starten →